Skip to main content

Table 2 Amplicon contributions for Patients UMX and UMY over a five-month time period

From: Combination of 16S rRNA variable regions provides a detailed analysis of bacterial community dynamics in the lungs of cystic fibrosis patients

Patient UMX

     

Patient UMY

 

Amplicon

(bp)*

M0a (%)

M3a (%)

M5b (%)

Amplicon

(bp)*

M0c (%)

M3d (%)

M5d (%)

Unique amplicons

       

352

P (2.34)

 

P (13.00)

    

351

P (1.67)

      

348

   

348

 

P (1.00)

P (33.88)

347

    

347

P (35.33)

 

120

  

P (1.88)

P (5.88)

120

  

119

  

P (1.88)

P (3.53)

119

  

113

  

P (3.77)

P (2.35)

113

  

111

   

P (3.53)

111

  

108

   

P (18.82)

108

  

100

    

100

P (4.66)

 

94

   

94

P (0.99)

P (0.81)

P (1.85)

87

   

87

  

P (2.47)

84

   

84

  

P (1.23)

76

   

76

P (1.84)

P (1.63)

P (4.94)

74

   

74

 

P (0.81)

 

71

   

71

 

P (4.07)

P (6.79)

70

P (4.36)

  

70

   

69

   

69

 

P (0.81)

 

67

   

67

 

P (0.81)

 

66

   

66

 

P (0.81)

 

65

   

65

  

P (3.70)

63

   

63

P (3.25)

 

P (3.09)

Shared amplicons

       

342

P (93.67)

P (100)

P (74.00)

342

P (61.67)

P (99.00)

P (34.16)

365

P (2.00)

  

365

P (3.00)

 

P (2.20)

350

  

P (13.00)

350

  

P (29.75)

115

 

P (3.77)

P (2.35)

115

 

P (0.81)

P (2.47)

112

P (16.50)

P (3.77)

P (4.71)

112

P (10.31)

P (0.81)

P (3.09)

103

P (4.85)

P (9.43)

P (5.88)

103

P (2.68)

 

P (1.23)

102

  

P (10.59)

102

P (8.62)

P (3.25)

P (29.63)

98

 

P (5.66)

P (8.24)

98

P (6.92)

P (6.50)

P (3.70)

93

 

P (3.77)

 

93

P (0.99)

P (0.81)

 

91

 

P (3.77)

P (4.71)

91

P (3.53)

P (1.63)

P (2.47)

88

P (12.13)

  

88

P (19.92)

P (1.63)

 

86

 

P (1.88)

 

86

 

P (13.01)

 

85

  

P (7.06)

85

  

P (6.79)

82

P (14.07)

  

82

P (2.97)

  

81

  

P (1.18)

81

P (2.12)

P (3.25)

P (3.70)

80

  

P (1.18)

80

 

P (2.44)

 

78

 

P (3.77)

P (1.18)

78

P (1.69)

P (3.25)

P (1.85)

77

P (8.73)

P (3.77)

P (5.88)

77

P (4.24)

P (1.63)

 

75

 

P (1.88)

 

75

P (2.26)

P (2.44)

 

73

P (8.73)

P (3.77)

P (3.53)

73

P (2.26)

P (3.25)

 

72

 

P (20.75)

 

72

P (1.27)

P (30.08)

P (11.73)

68

 

P (3.77)

 

68

 

P (0.81)

 

64

P (21.35)

  

64

 

P (0.81)

P (1.23)

62

 

P (3.77)

P (4.71)

62

P (18.79)

P (1.63)

P (2.47)

61

 

P (3.77)

 

61

  

P (1.23)

60

 

P (15.09)

P (4.71)

60

 

P (12.20)

P (3.70)

  1. *V1_V2 amplicons range from 300-400 bp whereas V1 amplicons range from 60-120 bp.
  2. M0, M3 and M5 refers to collection of samples at time 0, three and five months
  3. P indicates presence of amplicon with its percentage abundance in the individual profile for that specific region.
  4. aPatient UMX was treated with azithromycin, co-trimoxazole and tobramycin
  5. bPatient UMX was treated with co-trimoxazole
  6. cPatient UMY was treated with levofloxacin (Levaquin)
  7. dPatient UMY was treated with polymyxin E
Back to article page

Human Genomics

ISSN: 1479-7364